GNMLF (Genomma Lab InternacionalB de CV) Beneish M-Score : -2.35 (As of Mar. 23, 2025)

View and export this data going back to 2012. Start your Free Trial

What is Genomma Lab InternacionalB de CV Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.35 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Genomma Lab InternacionalB de CV's Beneish M-Score or its related term are showing as below:

GNMLF' s Beneish M-Score Range Over the Past 10 Years
Min: -3.61 Med: -2.54 Max: -1.81
Current: -2.35

During the past 13 years, the highest Beneish M-Score of Genomma Lab InternacionalB de CV was -1.81. The lowest was -3.61. And the median was -2.54.

Genomma Lab InternacionalB de CV Beneish M-Score Historical Data

The historical data trend for Genomma Lab InternacionalB de CV's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomma Lab InternacionalB de CV Beneish M-Score Chart

Genomma Lab InternacionalB de CV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Beneish M-Score

Get a 7-Day Free Trial

-2.45

-2.42

-2.63

-2.92

-2.35

Genomma Lab InternacionalB de CV Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Beneish M-Score	Get a 7-Day Free Trial															-2.92	-2.69	-2.60	-2.67	-2.35

Competitive Comparison of Genomma Lab InternacionalB de CV's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genomma Lab InternacionalB de CV's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's Beneish M-Score falls into.

Genomma Lab InternacionalB de CV Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Genomma Lab InternacionalB de CV for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 1.068

0.528 * 0.9539

0.404 * 1.0517

0.892 * 1.0449

0.115 * 0.7195

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 1.0205

4.679 * -0.032094

0.327 * 0.9374

-2.55

This Year (Dec24) TTM:

Last Year (Dec23) TTM:

Total Receivables was $259.3 Mil.
Revenue was 223.707 + 258.631 + 253.901 + 252.908 = $989.1 Mil.
Gross Profit was 141.049 + 166.173 + 162.537 + 165.078 = $634.8 Mil.
Total Current Assets was $594.5 Mil.
Total Assets was $1,154.7 Mil.
Property, Plant and Equipment(Net PPE) was $170.6 Mil.
Depreciation, Depletion and Amortization(DDA) was $19.0 Mil.
Selling, General, & Admin. Expense(SGA) was $407.5 Mil.
Total Current Liabilities was $323.8 Mil.
Long-Term Debt & Capital Lease Obligation was $242.9 Mil.
Net Income was 22.703 + 33.522 + 34.478 + 22.421 = $113.1 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0.0 Mil.
Cash Flow from Operations was 60.988 + 74.322 + 22.493 + -7.619 = $150.2 Mil.

Total Receivables was $232.3 Mil.
Revenue was 207.677 + 252.211 + 254.931 + 231.802 = $946.6 Mil.
Gross Profit was 124.468 + 157.412 + 155.437 + 142.232 = $579.5 Mil.
Total Current Assets was $628.6 Mil.
Total Assets was $1,221.8 Mil.
Property, Plant and Equipment(Net PPE) was $201.2 Mil.
Depreciation, Depletion and Amortization(DDA) was $15.6 Mil.
Selling, General, & Admin. Expense(SGA) was $382.2 Mil.
Total Current Liabilities was $390.1 Mil.
Long-Term Debt & Capital Lease Obligation was $249.4 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(259.266 / 989.147)	/	(232.312 / 946.621)
	=	0.262111	/	0.245412
	=	1.068

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(579.549 / 946.621)	/	(634.837 / 989.147)
	=	0.612229	/	0.641802
	=	0.9539

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (594.485 + 170.628) / 1154.721)	/	(1 - (628.623 + 201.176) / 1221.762)
	=	0.337404	/	0.320818
	=	1.0517

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	989.147	/	946.621
	=	1.0449

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(15.629 / (15.629 + 201.176))	/	(18.998 / (18.998 + 170.628))
	=	0.072088	/	0.100187
	=	0.7195

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(407.536 / 989.147)	/	(382.198 / 946.621)
	=	0.412008	/	0.40375
	=	1.0205

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((242.85 + 323.8) / 1154.721)	/	((249.433 + 390.141) / 1221.762)
	=	0.490725	/	0.523485
	=	0.9374

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(113.124 - 0	-	150.184)	/	1154.721
	=	-0.032094

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Genomma Lab InternacionalB de CV has a M-score of -2.55 suggests that the company is unlikely to be a manipulator.

Genomma Lab InternacionalB de CV Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Genomma Lab InternacionalB de CV's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Genomma Lab InternacionalB de CV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genomma Lab Internacional SAB de CV (OTCPK:GNMLF) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

LABB:Mexico GEKA:Germany

Address

Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210

Website

https://www.genommalab.com

Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.